Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform. We are building a rich pipeline of assets in four therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases.
The Kymouse strains have more base-pairs of the human immunoglobulin genes than any other model. Their performance is exceptional: virtually every mouse responds to challenge, producing high-titre polyclonal antibodies to a variety of antigens including highly conserved human antigens.
Latest funding size
Time since last funding
|Woodford Investment Management, Bill & Melinda Gates Foundation, Malin, Hepalink, Wellcome Trust, ORI Healthcare Fund, Woodford Patient Capital, Malin Corporation plc|